Article
Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.
Medical oncology (Northwood, London, England) - 1 Mar 2014
de Lima Luciene Terezina, Vivona Douglas, Bueno Carolina Tosin, Hirata Rosario D C, Hirata Mario H, Luchessi André D, de Castro Fabíola Attié, de Lourdes F Chauffaille Maria, Zanichelli Maria A, Chiattone Carlos S, Hungria Vania T M, Guerra-Shinohara Elvira M
Abstract excerpt
Imatinib mesylate (IM) has become a standard of care in chronic myeloid leukemia (CML) therapy. Single nucleotide polymorphisms (SNPs) and altered expression in drug transporter genes may influence IM response. In order to investigate whether mRNA expression and SNPs in drug transporters are associated with IM resistance, we studied 118 chronic-phase CML patients receiving the standard dose of IM (400 mg/day)....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.